Figure 5. Treatment with Exendin 9-39 normalizes the effects of SG on embryo size without affecting maternal glycemia.

(A and B) Oral glucose tolerance test and AUC in pregnant mice (E12.5) that had sham or SG surgery and were treated or not treated with Exendin 9-39 during pregnancy. (C and D) Nonfasting and fasting glucose levels of the 4 groups of mice. (E) Weight at E18.5 of the 4 experimental groups. (F and G) Corrected weight of P1 pups and the average weight of litters in the 4 experimental groups. (H) Fraction of SGA pups in the 4 experimental groups. (I) Scatter plot of birth weight as a function of fasting glycemia in E12.5. (J and K) Weight of male and female offspring of the 4 experimental groups. Blue: sham-operated mice or offspring of sham-operated mice untreated with Exendin 9-39 during pregnancy (full) or treated with Exendin 9-39 (dashed); Red: SG-operated mice or offspring of SG-operated mice untreated with Exendin 9-39 during pregnancy (full) or treated with Exendin 9-39 (dashed). *P < 0.05, **P < 0.01 by 2-way ANOVA with Tukey HSD post hoc test in B–J or by 3-way continuous measures ANOVA in A. In A–D, sham Ex9^– n = 14, sham Ex9⁺ n = 10, SG Ex9^– n = 6, SG Ex9⁺ n = 9; in E, sham Ex9^– n = 14, sham Ex9⁺ n = 10, SG Ex9^– n = 6, SG Ex9⁺ n = 9; in F, sham Ex9^– n = 155, sham Ex9⁺ n = 98, SG Ex9^– n =107, SG Ex9⁺ n = 85; in G, sham Ex9^– n = 16, sham Ex9⁺ n = 10, SG Ex9^– n =10, SG Ex9⁺ n = 8; in I, sham Ex9^– n = 13, sham Ex9⁺ n = 10, SG Ex9^– n = 6, SG Ex9⁺ n = 9; in J, sham Ex9^– n = 16, sham Ex9⁺ n = 16, SG Ex9^– n = 25, SG Ex9⁺ n = 11.